ADC Therapeutics SA (ADCT) Stock: Buy, Sell, or Hold?
ADCT - ADC Therapeutics SA
$1.49
-0.11 (-6.88%)
âŧ
5d:
+6.43%
30d:
+15.5%
90d:
+30.7%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When ADCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ADCT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ADCT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ADCT is currently trading at $1.49, which is considered slightly high relative to its 30-day fair value range of $1.11 to $1.54.
Technical Outlook: Technically, ADCT is showing sideways momentum. Immediate support is located at $1.39, while resistance sits at $1.87. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: ADCT scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.33 (+108.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADCT is showing sideways momentum. Immediate support is located at $1.39, while resistance sits at $1.87. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: ADCT scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.33 (+108.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.11 -
$1.54
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 108.3% below Wall St target ($3.33)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.11 -
$1.54
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.39
Resistance Level
$1.87
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.37
Wall Street Target
$3.33
(+108.3%)
Revenue Growth (YoY)
2.2%
Profit Margin
-121.8%
Share & Embed Analysis
Last updated: October 23, 2026 12:12 PM ET
Data refreshes hourly during market hours. Next update: 1:12 PM
Data refreshes hourly during market hours. Next update: 1:12 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
